Additionally, a clinical study suggested that the exenatide group showed clinically relevant improvements in PD across both motor and cognitive measures compared to the control group (Aviles-Olmos et al., 2013)
The current UK regulatory position maintains that: GLP-1 receptor agonists remain authorised for their approved indications (type 2 diabetes management for all agents
In a large study of over 18,000 patients, those taking tirzepatide lost about 15.3 percent of body weight in one year compared to 8.3 percent with semaglutide
GLP-1, or glucagon-like peptide-1, plays a crucial role in regulating our appetite and metabolism
Like other GLP-1R agonists, when used alone or treated with non-insulin secretagogues, DUL treatment is associated with weight loss or decreased weight gain (107)
Retatrutide storage and handling Proper storage protects your investment